Catalyst Wire Dossier Catalyst Wire Dossier

GS-9669

GS-9669 · Gilead Sciences
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for GS-9669, covering 2012-07-25 to 2015-05-21. Get the full timeline:

Most recent: Clinical Trial Update: Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection [Phase 2]

See pricing